February 2025 SCRI Release Copied
SCRI Trials and Trial Regimen Updates
The following updates were completed between Jan. 25, 2025, through Feb. 20, 2025. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens. For questions about these trials and regimens, please contact SCRIiKMEMRedits@McKesson.com.
New Builds Completed
| Study Number | Notes for New Build |
| 24130 | USOR 24130 BRE 436 Phase 2 Cohort 1 (Arm 1 and 2) BNT327 + Nab- Paclitaxel Q28D
USOR 24130 BRE 436 Phase 2 Cohort 2 Arm 1 BNT327 + Paclitaxel Q28D USOR 24130 BRE 436 Phase 2 Cohort 2 Arm 2 BNT327 + Gemcitabine + Carboplatin Q28D |
| 23164 | USOR 23164 LYM 240 Phase 1 Part B CB-010
USOR 23164 LYM 240 Phase 1 Part B Lymphodepletion Cyclophosphamide + Fludarabine |
| 24086 | USOR 24086 LYM 242 Phase 2 Bendamustine + Rituximab Q28D USOR 24086 LYM 242 Phase 2 Golcadomide + Rituximab Q28D USOR 24086 LYM 242 Phase 2 R-CHOP Q21D
USOR 24086 LYM 242 Phase 2 Rituximab Maintenance Q56D |
| 22260 | USOR 22260 RM 949 Phase 1a/b Cohort A2, B1, B2, C1 LOXO-435 Q21D
USOR 22260 RM 949 Phase 1a/b Cohort B3 LOXO-435 + Pembrolizumab Q21D |
| 24247 | USOR 24247 MM 192 Phase 3 Stage 2 Arm A (C13+) Mezigdomide + Carfilzomib D1,15 + Dexamethasone Q28D
USOR 24247 MM 192 Phase 3 Stage 2 Arm A Mezigdomide + Carfilzomib D1,8,15 + Dexamethasone Q28D USOR 24247 MM 192 Phase 3 Stage 2 Arm B Carfilzomib D1,2,8,9,15,16 + Dexamethasone Q28D USOR 24247 MM 192 Phase 3 Stage 2 Arm B Carfilzomib D1,8,15 + Dexamethasone Q28D |
| 24140 | USOR 24140 AML 74 Phase 1a/1b NMS-03597812 Q28D |
Updated Reference Information
| Study Number | Updated Reference Information | Updated Regimen Instructions | Other Changes |
|
22322 |
Amendment f: 22 Aug 2024 | NA | NA |
| 23245 | Amendment 01 Version 2.0: 11 Oct 2024 | NA | NA |
| 20186 | Version 6: 25 October 2024 | NA | NA |
| 23141 | Protocol Amendment 07: 13 Dec 2024 | NA | NA |
| 23076 | Version 4: 31OCT2024 | Order of administration updated | NA |
| 22325 | NA | Update IP preparation | NA |
| 23229 | NA | Update IP preparation | NA |
| 22067 | NA | Update IP preparation | NA |
| 23223 | Version 6.0: 19 Sep 2024 | Update IP administration language | Updated regimen title to include drug name |
| 23059 | Version 3: 06 Sep 2024 | NA | NA |
| 23141 | Protocol Amendment 07: 13 Dec 2024 | NA | NA |
| 21455 | Version 5: 02 Oct 2024 | NA | NA |
| 23051 | NA | Update IP preparation | NA |
| 18283 | Amendment 13: 19 Nov, 2024 | Update IP preparation | NA |